Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 5/20 | 0.67 |
| ▸ | PDE8A | O60658 | 10/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13596787 | 0.89 | PDE8A (0.62) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL1146545 | 0.86 | YTHDC1 (0.53) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL7204689 | 0.86 | PDE8A (0.60) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL2060472 | 0.86 | PDE4A (0.67) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL21076723 | 0.84 | PDE8A (0.57) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL23764385 | 0.83 | PDE8A (0.59) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL822875 | 0.83 | PDE8A (0.56) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL17802599 | 0.82 | CFTR (0.67) | YTHDC1PDE8APDE4DCDK1ADORA2A | |
| SCHEMBL2060105 | 0.82 | PDE8A (0.55) | YTHDC1PDE8APDE4APDE4BPDE4C | |
| SCHEMBL25511872 | 0.81 | MEN1 (0.59) | PDE8APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| WO-2017188287-A1 | SUBSTITUTED PURINE DERIVATIVE | 大日本住友製薬株式会社 | 2017-11-02 | — | — | WO | disclosed |
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | NR0B2, NR0B1, BRD7 | YTHDC1 1481/4885PDE8A 2677/4885PDE4A 3469/4885 |
| US-10703755-B2 | Substituted purine derivative | TLR7, TLR9, TLR1 | YTHDC1 360/4885PDE8A 1421/4885PDE4A 437/4885 |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | NR0B2, NR0B1, BRD7 | YTHDC1 1400/4885PDE8A 2864/4885PDE4A 3468/4885 |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | TLR7, TLR9, TLR1 | YTHDC1 360/4885PDE8A 1421/4885PDE4A 437/4885 |
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | YTHDC1 261/4885PDE8A 1775/4885PDE4A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.